



## CERTIFICATE OF ANALYSIS No.: 2024-14810

Work order:

Analysis ID:

Method ID:

Method SOP:

## CLIENT

Sample condition:

Sample ID:

Batch No.: \*

Sample type:

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

## SAMPLE \* DR KENT GLUCOSAMINE CBD CREAM

SUITABLE

KCG01124212A

2429011

Cream





16/07/2024 16/07/2024 17/07/2024 Nika Peterka

\* Information provided by the client.

| CANNABINOID PROFILE  |                            | Concentration<br>[% w/w]                 | Expanded<br>uncertainty<br>[% w/w] | Graphic presentation of relative cannabinoid concentration |
|--|----------------------------|--|------------------------------------|--|
| CBDV   | - Cannabidivarin           | <loq< th=""><th>n/a</th><th></th></loq<> | n/a                                |  |
| CBDA   | - Cannabidiolic acid       | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBGA   | - Cannabigerolic acid      | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBG  | - Cannabigerol             | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBD  | - Cannabidiol              | 1.096                                    | 0.055                              |  |
| THCV   | - Tetrahydrocannabivarin   | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBN  | - Cannabinol               | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| ∆ <sup>9</sup> -THC  | - Δ-9-Tetrahydrocannabinol | 0.0391                                   | 0.0086                             |  |
| ∆ <sup>8</sup> -THC  | - Δ-8-Tetrahydrocannabinol | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBL  | - Cannabicyclol            | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBC  | - Cannabichromene          | < LOQ                                    | n/a                                |  |
| $\Delta^9$ -THCA - $\Delta$ -9-Tetrahydrocannabinolic acid |                            | < LOQ                                    | n/a                                |  |
| CBV  | - Cannabivarin             | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBCA   | - Cannabichromenic acid    | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBT  | - Cannabicitran            | <loq< td=""><td>n/a</td><td></td></loq<> | n/a                                |  |
| CBE  | - Cannabielsoin            | < LOQ #                                  | n/a                                |  |

2024-111229

PHL\_RPC\_16C

MET-LAB-001-08

2024\_235

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

17/07/2024

End of Certificate

Approved by:

mag. Janja Ahej Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar Chief Technology Officer